Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSS40 in moderate to severe bone metastasis cancer pain
NCT07008703Phase 2Recruiting
- Sponsor
- 3SBio
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cancer pain comparing SSS40 with Placebo (2 arms). Primary endpoint: Adverse Events and Serious Adverse Events. Started Mar 2024; status: recruiting.
02
Drugs
sss40
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT07008703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07008703.